C4 Therapeutics director awarded 2,650 shares
Anderson Kenneth Carl reported acquisition or exercise transactions in this Form 4 filing.
Rhea-AI Filing Summary
Anderson Kenneth Carl reported acquisition or exercise transactions in this Form 4 filing.
C4 Therapeutics, Inc. director Kenneth C. Anderson received an equity award of common stock rather than cash fees for his board service. On July 1, 2026, he was granted 2,650 shares at a value based on the closing market price of $4.34 per share, in line with the company’s Non-Employee Director Compensation Policy. Following this compensation grant, Anderson directly holds 71,950 common shares. Additional shares are held indirectly through several Anderson family revocable and irrevocable trusts, for which he disclaims beneficial ownership except for any pecuniary interest.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 2,650 shares
Grant/Award
6 txns
Insider
Anderson Kenneth Carl
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 2,650 | $4.34 | $12K |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Common Stock — 71,950 shares (Direct);
Common Stock — 129,877 shares (Indirect, By Kenneth C. Anderson 2021 Irrevocable Trust);
Common Stock — 74,581 shares (Indirect, By Kenneth C. Anderson 2015 Irrevocable Trust);
Common Stock — 74,581 shares (Indirect, By Cynthia E. Anderson 2015 Irrevocable Trust);
Common Stock — 3,623 shares (Indirect, By Kenneth C. Anderson Revocable Trust);
Common Stock — 3,623 shares (Indirect, By Cynthia E. Anderson Revocable Trust)
Footnotes (7)
- F1. These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer.
- F2. The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on July 1, 2026.
- F3. Shares held by the Kenneth C. Anderson 2021 Irrevocable Trust. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
- F4. Shares held by the Kenneth C. Anderson 2015 Irrevocable Trust. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
- F5. Shares held by the Cynthia E. Anderson 2015 Irrevocable Trust. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
- F6. Shares held by the Kenneth C. Anderson Revocable Trust. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
- F7. Shares held by the Cynthia E. Anderson Revocable Trust. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
Key Figures
Director stock award: 2,650 shares
Award valuation price: $4.34 per share
Direct holdings after grant: 71,950 shares
+3 more
6 metrics
Director stock award
2,650 shares
Common stock grant as non-employee director compensation on July 1, 2026
Award valuation price
$4.34 per share
Based on closing market price of common stock on July 1, 2026
Direct holdings after grant
71,950 shares
Common stock directly held by Kenneth C. Anderson following the award
Cynthia E. Anderson Revocable Trust holdings
3,623 shares
Common stock held indirectly via Cynthia E. Anderson Revocable Trust
Kenneth C. Anderson 2015 Irrevocable Trust holdings
74,581 shares
Common stock held indirectly via 2015 Irrevocable Trust
Kenneth C. Anderson 2021 Irrevocable Trust holdings
129,877 shares
Common stock held indirectly via 2021 Irrevocable Trust
Key Terms
Non-Employee Director Compensation Policy, Revocable Trust, Irrevocable Trust, pecuniary interest, +1 more
5 terms
Non-Employee Director Compensation Policy financial
"issued in accordance with the Issuer's Non-Employee Director Compensation Policy"
Revocable Trust financial
"Shares held by the Kenneth C. Anderson Revocable Trust."
A revocable trust is a legal arrangement where the person who creates it keeps control and can change or cancel the trust at any time, while naming who will manage and receive the assets later. Think of it like a flexible folder for your investments and property that can be relabeled or reworked as circumstances change; it matters to investors because it determines how ownership is recorded, how easily assets transfer on incapacity or death, and whether holdings bypass public probate proceedings.
Irrevocable Trust financial
"Shares held by the Kenneth C. Anderson 2015 Irrevocable Trust."
An irrevocable trust is a legal arrangement where an owner transfers assets into a separate entity managed by a trustee and gives up the power to modify or reclaim those assets. For investors it matters because putting stock or other holdings into such a trust can change who controls and benefits from the assets, affect taxes and creditor protection, and influence how easy it is to sell or value those holdings—like placing valuables in a locked safe overseen by someone else.
pecuniary interest financial
"disclaims beneficial ownership of these shares except to the extent of his pecuniary interest"
Grant, award, or other acquisition financial
"transaction_code_description": "Grant, award, or other acquisition""
FAQ
What did C4 Therapeutics (CCCC) director Kenneth C. Anderson report in this Form 4?
Kenneth C. Anderson reported receiving an award of 2,650 shares of C4 Therapeutics common stock. The shares were issued as compensation for his service as a non-employee director, in place of a cash fee, under the company’s director compensation policy.
Does this C4 Therapeutics (CCCC) Form 4 show any open-market purchases or sales by Kenneth C. Anderson?
The Form 4 does not show open-market purchases or sales. It reports a grant of 2,650 shares as director compensation and multiple trust holdings entries, with no transactions coded as open-market buys or sells.
AI-generated analysis. How Rhea-AI works. Not financial advice.
